CONFERENCE COVERAGE
Consortium of Multiple Sclerosis Centers
Annual Meeting
2019 COVERAGE
- Multiple Sclerosis Flowsheet Deemed Acceptable by Clinicians, Staff
- Efficacy of ADS-5102 Extended Release for Impaired Walking in MS
- Focused Healthcare Practitioner Discussion Improves MS Relapse Outcomes
- Long-Term Reductions in MS Disability Progression After Ocrelizumab Treatment
- Integrative Medicine Model Shows Efficacy in Improving MS Treatment
- Structured Algorithm to Optimize Relapse Management in MS
- Dimethyl Fumarate Linked With Vulnerability to Herpes Simplex Encephalitis
- Alemtuzumab Improves QOL in MS Despite Thyroid Adverse Events
- Siponimod Treatment of SPMS: Neurologist Expectations
- Treatment Patterns of DMTs in Pediatric Patients With MS
- Alemtuzumab Improves Clinical, MRI Outcomes in MS Across all Age Groups
- Long DMD Lapses Associated With Higher Relapses, Resource Use, and Costs
Latest Tweets
Follow
@NeuroAdvisor
Conference Coverage from
